Literature DB >> 29648501

New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.

Nuala McNicholas1, Andrew Lockhart1, Siew M Yap1, Karen O'Connell1, Niall Tubridy1, Michael Hutchinson1, Christopher McGuigan1.   

Abstract

The International Panel on Diagnosis of Multiple Sclerosis (MS) recently revised the 2010 McDonald criteria and made recommendations for revision, allowing for the earliest possible, accurate diagnosis of MS. For relapsing-remitting MS, positive, unmatched cerebrospinal fluid oligoclonal bands may substitute for dissemination in time. Symptomatic lesions, including brainstem and spinal cord, may demonstrate dissemination in space or in time if enhancing (with the exception of the optic nerve). Cortical and juxtacortical lesions are equivalent. In this retrospective analysis, we applied revised criteria to 250 patients previously diagnosed with relapsing-remitting MS according to 2010 criteria and assessed for change in diagnostic times. There was a significant improvement in time to diagnosis between 2010 and 2017 groups ( p < 0.01). Median time to diagnosis according to McDonald 2010 was 7.4 months, compared with 2.3 months for McDonald 2017. Use of cerebrospinal fluid results most frequently resulted in a reduction in time to diagnosis. Symptomatic gadolinium-enhancing lesions led to earliest diagnostic times.

Entities:  

Keywords:  Multiple sclerosis; outcome measurement

Mesh:

Year:  2018        PMID: 29648501     DOI: 10.1177/1352458518770088

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  4 in total

Review 1.  Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.

Authors:  Andrew J Solomon; Robert T Naismith; Anne H Cross
Journal:  Neurology       Date:  2018-10-31       Impact factor: 9.910

2.  2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes.

Authors:  Lorenzo Gaetani; Luca Prosperini; Andrea Mancini; Paolo Eusebi; Maria Chiara Cerri; Carlo Pozzilli; Paolo Calabresi; Paola Sarchielli; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2018-09-08       Impact factor: 4.849

3.  Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.

Authors:  Stefan Bittner; Falk Steffen; Timo Uphaus; Muthuraman Muthuraman; Vinzenz Fleischer; Anke Salmen; Felix Luessi; Achim Berthele; Luisa Klotz; Sven G Meuth; Antonios Bayas; Friedemann Paul; Hans-Peter Hartung; Ralf Linker; Christoph Heesen; Martin Stangel; Brigitte Wildemann; Florian Then Bergh; Björn Tackenberg; Tania Kuempfel; Frank Weber; Uwe K Zettl; Ulf Ziemann; Hayrettin Tumani; Sergiu Groppa; Mark Mühlau; Carsten Lukas; Bernhard Hemmer; Heinz Wiendl; Ralf Gold; Frauke Zipp
Journal:  EBioMedicine       Date:  2020-05-24       Impact factor: 8.143

4.  Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers.

Authors:  Lorenzo Gaetani; Nicola Salvadori; Elena Chipi; Lucia Gentili; Angela Borrelli; Lucilla Parnetti; Massimiliano Di Filippo
Journal:  Neural Regen Res       Date:  2021-01       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.